Cite
HARVARD Citation
L. Zuo, . et al. (n.d.). 106P Zanubrutinib in combination with tislelizumab in patients with refractory diffuse large B cell lymphoma (DLBCL): A phase II study. Immuno-oncology technology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
L. Zuo, . et al. (n.d.). 106P Zanubrutinib in combination with tislelizumab in patients with refractory diffuse large B cell lymphoma (DLBCL): A phase II study. Immuno-oncology technology. p. . [Online].